ALLOB is the Company’s off-the-shelf, allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors, offering numerous advantages in product quality, injectable quantity, production, logistics and cost as compared to an autologous approach.
To address critical factors for the development and commercialisation of cell therapy products, Bone Therapeutics has established a proprietary, optimised production process that improves consistency, scalability, cost effectiveness and ease of use of ALLOB. This optimized production process significantly increases the production yield, generating 100,000 of doses of ALLOB per bone marrow donation. Additionally, the final ALLOB product will be cryopreserved, enabling easy shipment and the capability to be stored in a frozen form at the hospital level. The process will therefore substantially reduce overall production costs, simplify supply chain logistics, improve patient accessibility and facilitate global commercialisation.
ALLOB is currently in two Phase I/IIA proof-of-concept trials for treatment of delayed-union fractures and spinal fusion procedures .
ALLOB has been classified as a tissue-engineered product (non-combined) by the EMA under the ATMP regulation 1394/2007EC.
Warning: ALLOB is an investigational product and is not yet available for sale. This website is not intended to provide medical advice or as a substitute for professional healthcare. Consult your doctor or medical provider for information about your diagnosis, treatment or condition.